SCHEMBL4263386

SCHEMBL4263386

O=C1COc2ccc(-c3ccn(-c4ccccc4)n3)cc2N1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NR3C2 P08235 8/20 0.63
ALDH1A1 P00352 5/20 0.53
KDM4E B2RXH2 4/20 0.53
RAB9A P51151 3/20 0.53
MAPT P10636 6/20 0.53
HPGD P15428 2/20 0.53
KMT2A Q03164 2/20 0.53
RXFP1 Q9HBX9 1/20 0.53
NR3C1 P04150 3/20 0.50
NPC1 O15118 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
AKT1 P31749 1/20 0.50
AKT2 P31751 1/20 0.50
AKT3 Q9Y243 1/20 0.50
LMNA P02545 1/20 0.49
HTT P42858 1/20 0.49
PGR P06401 2/20 0.48
MAPK1 P28482 1/20 0.48
AR P10275 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4267317 0.82 NR3C2 (0.73) NR3C2ALDH1A1KDM4EMAPTHPGD
SCHEMBL4294236 0.77 NR3C2 (1.00) NR3C2ALDH1A1KDM4ERAB9AKMT2A
SCHEMBL304764 0.77 MAPT (0.62) NR3C2ALDH1A1KDM4EMAPTHPGD
SCHEMBL12405077 0.75 MAPT (0.58) NR3C2ALDH1A1KDM4ERAB9AMAPT
SCHEMBL4289111 0.75 NR3C2 (0.72) NR3C2KMT2ANR3C1PGRAR
SCHEMBL4286851 0.75 NR3C2 (0.83) NR3C2NR3C1PGR
SCHEMBL30345214 0.75 SMN1; SMN2 (0.55) ALDH1A1KDM4ERAB9AMAPTHPGD
SCHEMBL4290160 0.75 NR3C2 (0.57) NR3C2KMT2ANR3C1PGRAR
SCHEMBL4272980 0.73 MAPT (0.59) NR3C2ALDH1A1KDM4ERAB9AMAPT
SCHEMBL4267996 0.72 POLB (0.77) ALDH1A1KDM4ERAB9AMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2009-02-26 US claimed
JP-2008508314-A 2008-03-21 JP claimed
EP-1778242-A2 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2007-05-02 EP claimed
WO-2006015259-A2 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2006-02-09 WO claimed
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2009-02-26 US disclosed
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2009-02-26 US disclosed
EP-1778242-A2 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2007-05-02 EP disclosed
WO-2006015259-A2 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2006-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS NR5A1, ESRRA, NR3C1 NR3C2 7/4885ALDH1A1 3483/4885KDM4E 2686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.